Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ChromaDex Corporation (CDXC) stocks in Canada

Learn how to easily invest in ChromaDex Corporation stocks.

ChromaDex Corporation is a biotechnology business based in the US. ChromaDex Corporation stocks (CDXC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $9.16 – a decrease of 9.52% over the previous week. ChromaDex Corporation employs 110 staff and has a trailing 12-month revenue of around $65.1 million.

How to buy shares in ChromaDex Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CDXC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy ChromaDex Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted ChromaDex Corporation's stock price?

Since the stock market crash in March caused by coronavirus, ChromaDex Corporation's stock price has had significant negative movement.

Its last market close was $2.85, which is 28.93% down on its pre-crash value of $4.01 and 14.00% up on the lowest point reached during the March crash when the stocks fell as low as $2.5.

If you had bought $1,000 worth of ChromaDex Corporation stocks at the start of February 2020, those stocks would have been worth $600.48 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $673.77.

ChromaDex Corporation stock price (NASDAQ:CDXC)

Use our graph to track the performance of CDXC stocks over time.

ChromaDex Corporation shares at a glance

Information last updated 2022-01-19.
Latest market close$2.85
52-week range$2.84 - $23.66
50-day moving average $4.56
200-day moving average $7.23
Wall St. target price$14.80
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.43

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

ChromaDex Corporation price performance over time

Historical closes compared with the close of $2.85 from 2022-01-18

1 week (2022-01-12) -9.52%
1 month (2021-12-17) -32.46%
3 months (2021-10-19) -53.66%
6 months (2021-07-19) -69.16%
1 year (2021-01-19) -39.43%
2 years (2020-01-17) -34.63%
3 years (2019-01-18) 3.34
5 years (2017-01-19) 2.88

ChromaDex Corporation financials

Revenue TTM $65.1 million
Gross profit TTM $35.3 million
Return on assets TTM -36.71%
Return on equity TTM -101.57%
Profit margin -42.83%
Book value $0.52
Market capitalisation $194.6 million

TTM: trailing 12 months

ChromaDex Corporation share dividends

We're not expecting ChromaDex Corporation to pay a dividend over the next 12 months.

Have ChromaDex Corporation's shares ever split?

ChromaDex Corporation's shares were split on a 1:3 basis on 12 April 2016. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ChromaDex Corporation shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for ChromaDex Corporation shares which in turn could have impacted ChromaDex Corporation's share price.

ChromaDex Corporation share price volatility

Over the last 12 months, ChromaDex Corporation's shares have ranged in value from as little as $2.84 up to $23.66. A popular way to gauge a stock's volatility is its "beta".

CDXC.US volatility(beta: 1.64)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ChromaDex Corporation's is 1.6442. This would suggest that ChromaDex Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

ChromaDex Corporation overview

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN. com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site